摘要
肺动脉高压是一种由已知或未知原因引起的以肺血管收缩、重构、原位血栓形成为主要病变特征,肺血管阻力进行性升高及血流受限,肺动脉压力异常升高的病理生理综合征,最终可导致右心功能受损,甚至死亡。恢复血管内皮结构和功能的完整性,逆转肺血管重构,促进血管新生替代永久性闭塞血管是治疗肺动脉高压的关键。近年研究发现,内皮祖细胞在维持血管内稳态、逆转肺血管重构及促进血管新生方面有重大意义,本文就肺动脉高压的内皮祖细胞治疗作一综述。
Pulmonary hypertension is a disease characterized by pulmonary vasoconstriction, pulmonary vascular remodeling andin situ thrombosis, resulting in pulmonary vascular resistance increasing and blood flow restriction, pulmonary artery pressure elevating, eventually leading to right heart dysfunction, even death. Remedy of the integrity of endothelial structure and function, pulmonary vascular remodeling, angiogenesis replace permanent vascular occlusion, is the key to the treatment of pulmonary hypertension. Recent studies have found that endothelial progenitor cells （EPCs） play an important role in maintaining vascular homeostasis and reversal pulmonary vascular remodeling and promote angiogenesis, this article made a summary on the EPCs for the treatment of pulmonary hypertension.
出处
《中华临床医师杂志（电子版）》
CAS
2015年第15期92-97,共6页
Chinese Journal of Clinicians(Electronic Edition)
基金
安徽高校自然科学研究重点项目(KJ2015A159)
安徽呼吸病临床基础实验室
安徽省实验室绩效考核项目(1406c085026)
关键词
高血压
肺性
内皮祖细胞
治疗
Hypertension,pulmonary
Endothelial progenitor cells
Treatment
